Wang L, Gintzler A R
Department of Biochemistry, State University of New York, Health Science Center at Brooklyn 11203, USA.
J Neurochem. 1997 Jan;68(1):248-54. doi: 10.1046/j.1471-4159.1997.68010248.x.
This laboratory has demonstrated that the longitudinal muscle/myenteric plexus (LMMP) preparation manifests pleiotropic responses to opioid agonists. For example, the mu-selective opiate receptor agonist sufentanil can produce a naloxone-reversible increase or decrease in the electrically stimulated formation of cyclic AMP, depending on its concentration. The present study demonstrates that the sufentanil facilitation and inhibition of stimulated cyclic AMP formation are mediated via Gs- and Gi-like G proteins, respectively. Inactivation of Gi (via pertussis toxin) not only abolishes sufentanil inhibition of cyclic AMP formation but also unmasks a facilitory effect. The latter response is eliminated following treatment with cholera toxin. In tolerant/dependent LMMP tissue, previously inhibitory concentrations of sufentanil produce a facilitation of cyclic AMP formation. However, this unmasked facilitory effect is resistant to cholera toxin. Thus, although inactivation of the inhibitory signal transduction pathway (via pertussis toxin) is sufficient to unmask excitatory sufentanil effects in opiate naive preparations, this mechanism cannot explain the reversal of sufentanil inhibition to facilitation that is observed in tolerant/dependent tissue. Instead, the chronic morphine-induced emergence of a mu-opiate receptor-coupled facilitory pathway that is either not expressed or not fully manifest in opiate naive LMMP tissue is suggested.
本实验室已证明,纵行肌/肠肌间神经丛(LMMP)制剂对阿片类激动剂表现出多效性反应。例如,μ选择性阿片受体激动剂舒芬太尼可根据其浓度,使电刺激诱导的环磷酸腺苷(cAMP)生成增加或减少,且这种增减可被纳洛酮逆转。本研究表明,舒芬太尼对刺激诱导的cAMP生成的促进和抑制作用分别通过类Gs和类Gi G蛋白介导。Gi失活(通过百日咳毒素)不仅消除了舒芬太尼对cAMP生成的抑制作用,还揭示出一种促进作用。用霍乱毒素处理后,后一种反应消失。在耐受/依赖的LMMP组织中,先前具有抑制作用的舒芬太尼浓度可促进cAMP生成。然而,这种揭示出的促进作用对霍乱毒素具有抗性。因此,尽管抑制性信号转导途径失活(通过百日咳毒素)足以在未接触阿片类药物的制剂中揭示舒芬太尼的兴奋作用,但这种机制无法解释在耐受/依赖组织中观察到的舒芬太尼抑制作用向促进作用的逆转。相反,提示慢性吗啡诱导出了一种μ阿片受体偶联的促进途径,该途径在未接触阿片类药物的LMMP组织中未表达或未完全显现。